Introduction {#S1}
============

Obesity is a disease caused by energy imbalance ([@B59]; [@B114]). Appetite, food consumption and exercise are only some of the parameters that regulate energy balance. In fact, obesity is a polygenic disease, and its etiology is determined by multiple factors such as neural circuits, hormones, nutrient absorption, lipid storage, lipid metabolism and inflammation ([Figure 1](#F1){ref-type="fig"}). Besides, obesity is a risk factor for cancer and cardiovascular diseases such as type 2 diabetes mellitus, hypertension, hypercholesterolemia, hyperlipidemia, coronary artery disease, and stroke. In the United States, it is estimated that one-third of adults and one-sixth of children are obese ([@B89]; [@B32]). The economic impact of obesity is estimated to be more than \$100 billion per year in the United States alone ([@B54]). Hence, better understanding of the mechanisms that regulate obesity and approaches to treat this disease are urgently needed. In this article, we will describe exciting new discoveries regarding the role of lymphatic vasculature in metabolic regulation and obesity.

![Relationship between obesity and lymphatic vasculature. Obesity is influenced by many parameters, such as inflammation, lipid absorption, adipogenesis, type 2 diabetes, appetite, genetics, exercise, and energy expenditure. Increasing evidences have suggested that the lymphatic vasculature could be participating in the development of obesity by regulating lipid absorption, adipogenesis and inflammation.](fphys-11-00003-g001){#F1}

Functions of the Lymphatic Vasculature {#S2}
======================================

Lymphatic vasculature absorbs interstitial fluid and returns it to blood circulation ([@B112]; [@B45]). Lacteals are specialized lymphatic vessels in the intestine, which absorb digested lipids ([@B12]; [@B94]). Lymphatic vessels are also important for clearing low-density lipoprotein particles from the skin and arteries by reverse cholesterol transport ([@B83]). Furthermore, lymphatic vasculature regulates the immune response ([@B96]). Lymphatic endothelial cells (LECs) secrete cytokines such as CCL19 and CCL21 to recruit activated dendritic cells and transport them to lymph nodes to promote T- and B-cell activation ([@B96]). LECs could directly present antigens to immune cells and promote peripheral immune tolerance ([@B99]). In summary, lymphatic vasculature regulates fluid homeostasis, lipid absorption, and immune response.

Lymphatic Vascular Architecture {#S3}
===============================

Lymphatic vasculature is made of LECs. LECs express unique markers that distinguish them from blood vascular endothelial cells. These markers include prospero-related homeobox 1 transcription factor (PROX1) ([@B131]), the tyrosine kinase receptor vascular endothelial growth factor 3 (VEGFR3/Flt4) ([@B62]), the transmembrane *O*-glycoprotein podoplanin ([@B17]) and neuropilin 2 (NRP2) ([@B134]). Endothelial cell junction proteins such as VE-cadherin, claudin-5, and PECAM-1 are expressed in all LECs. However, these junctional molecules are organized in different patterns to generate two functionally distinct structures within the lymphatic vasculature: lymphatic capillaries and collecting lymphatic vessels. Lymphatic capillaries have discontinuous "button-like junctions," which allows immune cells, interstitial fluid, and digested lipids to enter the vessels ([@B9]; [@B133]). Lymphatic capillaries are connected to the surrounding tissues by anchoring filaments, which respond to changes in external fluid pressure by opening the button-like junctions to allow the entry of leukocytes and interstitial fluid into the vessels ([@B60]; [@B118]). Unlike lymphatic capillaries, collecting vessels have continuous "zipper-like" endothelial junctions that prevent lymph leakage ([@B9]; [@B133]). Collecting vessels are covered with continuous basement membrane and lymphatic muscle cells with contractile ability ([@B20]; [@B122]; [@B121]). Collecting lymphatic vessels contain lymphatic valves (LVs), which regulate the unidirectional flow of lymph. Lymph flows through a series of lymph nodes where the immune cells and antigens are filtered out. Ultimately lymph is returned to blood circulation through two-pairs of lymphovenous valves (LVVs) located bilaterally at the junction of jugular and subclavian veins ([@B90]; [@B45]).

In the intestine, cholesterol, long-chain fatty acids, and fat-soluble vitamins are absorbed by intestinal epithelial cells, and repackaged in enterocytes into large (200--1000 nm) triglyceride-loaded particles called "chylomicrons" ([@B119]; [@B135]). Each intestinal villus contains a single lacteal, which is a lymphatic capillary with button-like junctions ([@B135]). Most chylomicrons are absorbed by the lacteals, from which they are transported to submucosal and mesenteric collecting lymphatic vessels, then into the thoracic duct, and finally to the blood circulation ([@B90]; [@B97]). Thus, digested lipids bypass the liver and are accessible to other organs and cells prior to the liver ([@B3]).

Lymphatic Vascular Dysfunction Results in Lymphedema {#S4}
====================================================

Structural and functional defects of lymphatic vascular system can lead to lymphedema, which is characterized by localized accumulation of interstitial fluid and tissue swelling ([@B82]). Although lymphedema is not a life-threatening disease, it could cause functional disability, skin infection, inflammation fibrosis and pain ([@B84]; [@B35]; [@B18]). Lymphedema is classified into either primary or secondary lymphedema. Primary lymphedema is caused by mutations in genes that regulate lymphatic vascular development. These genetic defects result in structural and functional defects in LECs, LVs, or LVVs. Primary lymphedema is typically present early in life (infancy, childhood, or puberty), and rarely appears in adulthood (older than age of 35) ([@B50]). Secondary lymphedema is caused by surgery (removal of lymph nodes) or radiation therapy in cancer patients, infection or trauma. Secondary lymphedema is much more prevalent than primary lymphedema, and is an increasing clinical problem due to the improving survival rates of cancer patients ([@B130]; [@B98]).

Clinical Correlations Between Obesity And Lymphedema {#S5}
====================================================

There is reciprocal relationship between obesity and lymphatic dysfunction. Obesity is one of the risk factors for the development of secondary lymphedema in breast cancer patients ([@B128]; [@B56]; [@B84]). In a study that compared 137 breast cancer patients, those with a body mass index (BMI) greater than 30 showed three times higher risk for developing upper extremity lymphedema compared with patients with lower BMI ([@B56]). A similar result was observed in a second independent study involving 282 breast cancer patients ([@B128]).

Obesity could result in lymphedema in the absence of other risk factors such as primary lymphedema, inguinal lymphadenectomy or radiation treatment ([@B51]; [@B6]). In a study with a small cohort of 15 obese individuals, the average BMI of the patients with lymphedema (70.1) was much higher than the BMI of obese patients without lymphedema (42.0) ([@B51]). Another clinical study demonstrated that lean, healthy men (BMI: 22.3) showed better adipose tissue lymphatic drainage when compared with obese, but otherwise healthy men with normal glucose tolerance (BMI: around 35.7) ([@B6]).

Impaired lymphatic function could also lead to adipose tissue accumulation and fibrosis ([@B21]). Secondary lymphedema patients tend to have higher BMI compared to breast cancer survivors without lymphedema ([@B2]). Lymphedema patients have more adipocytes in the edematous tissues. The edematous tissues are infiltrated with macrophages and lymphocytes, which promote the proliferation and hypertrophy of local adipocytes ([@B22]; [@B46]). Adipose tissue-derived stem cells from lymphedema patients are more potent in their ability to undergo adipogenic differentiation *in vitro* when compared to cells derived from control patients ([@B79]). Taken together, these results suggest that chronic lymphedema creates an inflamed environment, which promotes adipose tissue accumulation ([@B31]). Nevertheless, lymphedema could reduce mobility and thereby reduce energy expenditure. Hence, is adipogenesis a direct outcome of lymphedema or is it indirectly caused by chronic immobility that is associated with lymphedema? This important question was addressed in part by recent studies, which have suggested that exercise (yoga, stretching, strength training) could improve breast cancer-related lymphedema ([@B11]; [@B91]). These studies must be very encouraging to lymphedema patients as they suggest that lymphedema-associated adipogenesis could be controlled by exercise.

Lipedema: A Painful Disease That Affects Lymphatic Vasculature and Adipocytes {#S6}
=============================================================================

Lipedema is a disease characterized by the swelling of the legs due to the deposition of subcutaneous adipose tissue in the legs, thighs and buttocks ([@B115]). Most lipedema patients have high BMI, either in the overweight (25 to 30) or obese range (\>30) ([@B39]). However, lipedema patients are less prone to type 2 diabetes mellitus, hypertension and dyslipidemia indicating that lipedema is distinct from obesity ([@B40]; [@B4]). Wold et al. proposed a series of criteria to diagnose lipedema in 1940s that is still in use ([@B29]). These criteria include: (1) occurrence almost exclusively in women; (2) bilateral and symmetrical nature of adipose tissue accumulation with minimal involvement of the feet or ankle; (3) minimal pitting edema; (4) pain, tenderness and easy bruising; (5) persistent swelling of lower extremities despite elevation or weight loss ([@B29]). The cause of lipedema is still unclear; however, there is evidence that hormonal and hereditary influence may play a role in the development of lipedema ([@B40]). Important for this work, lipedema patients often show abnormal lymphoscintigraphic pattern with slow lymph flow ([@B13]). Ultrasound, MRI, and lymphangiogram are helpful for clinical diagnosis of lipedema ([@B125]). However, the test results may show "normal lymphatic function" in the early stage of the disorder ([@B40]; [@B82]; [@B29]). Consequently, lipedema is often misdiagnosed as obesity ([@B40]; [@B82]; [@B47]; [@B106]). Hence, whether lymphatic stasis in these patients cause increased adipogenesis or vice versa remains unknown.

Mouse Models That Highlight the Role of Lymphatic Vasculature on Metabolism and Obesity {#S7}
=======================================================================================

As described in the previous sections, there is strong clinical correlation between lymphatic dysfunction and adipogenesis. In this section we will discuss evidence from mouse models, which allows us to determine causality.

PROX1 {#S7.SS1}
-----

*Prox1* heterozygous mice develop chylous ascites (leakage of lipid−rich lymph into the peritoneal cavity) soon after birth ([@B55]). These *Prox1*^+/−^ mice develop adipocyte hypertrophy (increase in the size of adipocytes), increased serum free fatty acids, fatty liver and obesity in adulthood. Conditional deletion of one allele of *Prox1* from endothelial cells recapitulated this phenotype. In addition, overexpression of *Prox1* in the LECs rescues the obese phenotype of *Prox1* heterozygous mice ([@B36]). Furthermore, lymph could stimulate adipogenesis *in vitro* ([@B55]). Together these results suggest that leakage of lymph triggers the onset of adipogenesis and obesity in *Prox1*^+/−^ mice ([@B55]; [@B36]).

Obesity is mainly defined as a disease of energy imbalance. Young non-obese *Prox1*^+/−^ mice do not consume more food compared to their control littermates. In contrast, older obese *Prox1*^+/−^ mice consume less food and exercise less when compared with controls ([@B55]). What promotes the transition between these metabolic states is currently unknown. Adipocyte inflammation is known to reduce energy expenditure and lower food consumption ([@B78]; [@B136]). Hence, it is possible that the adipocyte inflammation observed in *Prox1*^+/−^ mice ([@B55]) might be contributing to the onset of obesity in older mice.

The obese phenotype of *Prox1*^+/−^ mice is strain dependent. *Prox1*^+/−^ and Tie2-Cre; *Prox1*^+/f^ mice bred in the NMRI background develop obesity ([@B55]). However, conditional deletion of one allele of *Prox1* using lymphatic vasculature-specific *Lyve1-Cre* in a non-NMRI background does not result in obesity ([@B36]). The reason for this strain-specific onset of obesity remains to be determined. Nevertheless, PROX1 is expressed in many metabolism-related organs (see below). Hence, it is worth investigating whether PROX1 might be playing additional LEC-independent roles in regulating obesity.

PROX1 is necessary for the development of liver ([@B110]; [@B105]). Obese *Prox1*^+/−^ mice develop hepatosteatosis (fatty liver disease) ([@B55]). This observation is consistent with the fact that PROX1 is important for the maintenance of lipid homeostasis in the liver. In the hepatocytes PROX1 interacts with HDAC3 to down-regulate the expression of genes such as *G0s2*, *Elovl6*, *Mfsd2a*, and *Cidec*, which are involved in lipid synthesis and lipolysis ([@B26]; [@B5]). Reducing PROX1 expression by AAV-based shRNA resulted in an increase in triglyceride levels in the mouse liver ([@B5]). In addition, treatment of mice with rapamycin causes hyperlipidemia by lowering PROX1 expression in the liver ([@B72]).

PROX1 is important for the development of pancreatic endocrine cells and glucose metabolism. Conditional deletion of *Prox1* in pancreatic progenitors of mice showed delayed embryonic islet cell genesis and damage of ductal tissue in adulthood ([@B129]). Overexpression of *Prox1* in immature β-cells promotes acute hyperglycemia ([@B92]). Consistent with these reports single-nucleotide polymorphisms in *PROX1* are associated with higher fasting glucose levels and type 2 diabetes mellitus ([@B76]; [@B71]; [@B53]; [@B1]). Furthermore, hyperinsulinemia is observed in obese *Prox1*^+/−^ mice ([@B55]). However, whether it is due to lymphatic dysfunction or pancreatic defects is currently unknown. Insulin treatment is associated with weight gain in human patients ([@B100]). Hence, whether increased plasma insulin levels might contribute to obesity in *Prox1*^+/−^ mice could be investigated.

Skeletal muscle is an important tissue for glucose metabolism and fat (mainly free fatty acid) storage ([@B42]). Besides, metabolic rate of skeletal muscles is an important index of resting energy expenditure ([@B137]). Skeletal muscles are composed of slow muscle fibers and fast muscle fibers, which generate energy through aerobic and anaerobic mechanisms respectively. Obesity in humans is inversely correlated with proportion of slow muscle fibers ([@B124]). *Prox1* is expressed in the satellite cells and slow muscle fibers. Conditional deletion of *Prox1* in skeletal muscles switched the slow muscle fibers to fast muscle fibers ([@B69]). In contrast, overexpression of PROX1 converted fast muscle fibers to slow muscle fibers. These results suggest that *Prox1* may play a critical metabolic role by regulating the identity of muscle fibers ([@B69]).

*Prox1* is expressed in brain regions, such as cortex, hippocampus, thalamus, hypothalamus, and cerebellum during embryonic and post-natal stages ([@B43]; [@B75]). Importantly, PROX1 is expressed in the paraventricular nucleus and the arcuate nucleus of the hypothalamus ([@B75]), which are directly involved in appetite control and feeding behavior ([@B41]). *Prox1* is a key factor for granule cell formation, maturation and differentiation during developmental stages ([@B74]). *Prox1* is important for adult neurogenesis in dentate gyrus and subventricular zone ([@B74]; [@B24]). However, whether PROX1 regulates the formation and/or functioning of the appetite centers of the brain remains to be investigated.

PROX1 is not expressed in retroperitoneal adipocytes ([@B55]). However, PROX1 is reported to be expressed in subcutaneous and omental adipose tissues ([@B95]). Whether PROX1 is expressed in adipocyte progenitors and whether it could regulate adipocyte lineage in an epigenetic manner is unknown.

In summary, based on the known roles of PROX1 in metabolic tissues we are tempted to speculate that PROX1 might be controlling certain aspects of obesity in non-lymphatic tissues. Obesity has not been reported in mice that are heterozygous for *Prox1* specifically in the liver, pancreas, brain, or muscle. Hence, it is possible that obesity arises in *Prox1*^+/−^ mice as a consequence of metabolic defects in multiple tissues as reported for another transcription regulator TRIM28 ([@B33]). PROX1 regulates the expression of mitochondrial lipid transporter CPT1a in LECs ([@B132]). Through this metabolic pathway PROX1 promotes epigenetic changes that support lymphangiogenesis. Whether PROX1 regulates CPT1a expression in other tissues, and whether this pathway could contribute to the onset of obesity in *Prox1*^+/−^ mice needs to be evaluated.

VEGF-C, VEGF-D, and VEGFR3 {#S7.SS2}
--------------------------

VEGF-C/VEGFR3 signaling is critical for lymphatic vascular development. *Vegfc^--/--^* mice lack lymphatic vessels due to a failure of LEC budding from the embryonic veins ([@B65]; [@B52]). Mutations in *VEGFR3* and *VEGF-C* are associated with congenital lymphedema ([@B38]; [@B19]; [@B48]). Subcutaneous fat is observed in *Chy* mice carrying an inactivating point mutation in the kinase domain of VEGFR3 ([@B66]). However, obesity is not observed in *Chy* mice ([@B7]) indicating that obesity and adipogenesis are not necessarily correlated.

Deletion of *Vegfc* in adult mice caused the regression of intestinal lacteals, reduced lipid absorption and provided resistance to high fat diet-induced obesity ([@B88]). Likewise, K14-VEGFR3-Ig mice in which a soluble form of extracellular VEGFR3 (sVEGFR3) that traps VEGF-C and VEGF-D was expressed from keratinocytes, were also resistant to high fat diet induced obesity, hepatic lipid accumulation and metabolic dysfunction ([@B63]). In contrast, overexpression of VEGF-C in the keratinocytes resulted in weight gain, hepatic lipid accumulation, subcutaneous adipose tissue accumulation and insulin resistance even in chow diet fed mice ([@B64]). Furthermore, an increased number of pro-inflammatory macrophages were found in the white adipose tissue of the VEGF-C overexpression mice ([@B64]). These results suggest that the pro-lymphangiogenic VEGF-C is also a pro-inflammatory and pro-obesogenic molecule. These results are consistent with the observation that obese patients have elevated levels of VEGF-C in their serum ([@B108]; [@B123]).

Gut microbiota are important regulators of metabolism and energy balance ([@B86]; [@B28]). Depletion of gut microbiota leads to morphological defects in lacteals ([@B111]). Gut microbiota stimulates macrophages of the intestinal villi to produce VEGF-C. Lack of gut microbiota causes the transformation of button-like junctions of lacteals into zipper-like junctions due to reduced VEGF-C signaling ([@B111]). This junctional transformation reduced lipid absorption in the gut ([@B111]). Taken together, these results suggest that gut microbiota may play a role in obesity and metabolic syndrome by regulating VEGF-C signaling.

VEGF-D is an additional ligand of VEGFR3. Deletion of *Vegfd* in mice does not result in any obvious lymphatic defects ([@B8]). However, overexpression of VEGF-D can induce lymphangiogenesis and angiogenesis under normal and pathological conditions ([@B8]; [@B23]). Overexpression of VEGF-D in lungs, kidneys, and adipose tissue induces hyperplasia of lymphatic vessels and lymphangiectasia ([@B73]). Moreover, long-term overexpression of VEGF-D in adipose tissue of mice caused increased macrophage infiltration and enhanced adipose tissue fibrosis ([@B73]). However, overexpression VEGF-D did not result in obesity or insulin resistance in chow diet fed mice ([@B73]). Surprisingly, in high-fat diet fed condition overexpression of VEGF-D in the adipocytes resulted in enhanced glucose clearance, lower insulin levels and reduced liver triglycerides ([@B25]). Total F4/80^+^ macrophages were reduced in subcutaneous adipose tissue by increased immune trafficking from the tissue. These results suggest that enhanced VEGF-D signaling in the adipose tissue might reduce obesity associated-immune cell accumulation and improve metabolic response ([@B25]).

These unexpected and somewhat contradictory roles of VEGF-C, VEGF-D, and VEGFR3 call for further investigation of this signaling pathway in metabolic disorders and obesity.

Neuropilin {#S7.SS3}
----------

Neuropilins 1 and 2 (NRP1 and NRP2) were originally identified as molecules that are necessary for the patterning of neurons ([@B68]; [@B70]). NRPs were found to function as co-receptors of VEGF-receptors in endothelial cells ([@B16]). NRP1 is mainly expressed in arteries and NRP2 is expressed in veins and lymphatic vessels ([@B57]; [@B134]). VEGF-A associates with NRP1/VEGFR1 complex to induce angiogenesis ([@B109]; [@B135]). VEGF-C associates with NRP2/VEGFR2/VEGFR3 complex to regulate lymphangiogenesis ([@B37]; [@B16]; [@B34]). NRPs also interact with secreted and transmembrane ligands known as semaphorins ([@B70]). There are eight classes of SEMA family (SEMA1-7; SEMAV); of which, SEMA3-7 are found in vertebrates ([@B85]). NRPs can interact with members of SEMA3 family. SEMA3/NRP complexes further interact with transmembrane proteins called plexins. Plexins regulate the development of many organs, such as skeleton and kidney, and participate in angiogenesis and vascular patterning ([@B93]). SEMA3/NRP1/PlexinA1 complex regulates LV morphogenesis ([@B16]; [@B61]).

*Nrp1* knockout mice are embryonic lethal at E12.5. *Nrp1^--/--^* mice exhibited vascular defects such as agenesis and transposition of great vessels, and disorganized and insufficient development of vascular networks in the yolk sac ([@B67]). Global overexpression of *Nrp1* results in ectopic blood vascular sprouting, dilated vessels, and abnormal heart ([@B68]).

Lacteals are made of LECs with discontinuous button-like junctions. These button-like junctions allow the easy passage of large chylomicrons into the lacteals. Deletion of *Nrp1* or *Vegfr1* by inducible endothelial- specific Cre resulted in the transition of button-like junctions of lacteals into zipper-like junctions ([@B135]). Knock out of *Nrp1* or *Vegfr1* in blood endothelial cells enhances the bioavailability of VEGF-A and downstream signaling through VEGFR2 in LECs. High VEGFR2 signaling activity promotes zipper-like junctions in lacteals. Increased number of zipper-like junctions in mice lacking NRP1 or VEGFR1 reduced chylomicron uptake and also increased their resistance to high-fat diet-induced obesity ([@B135]).

*Nrp2*-null mice are viable but have hypoplastic lymphatic capillaries compared with littermate controls ([@B134]). Whether LEC-specific deletion of *Nrp2* affects metabolism is currently not known.

Neuropilins and their ligands play an additional-complex role in energy homeostasis through the nervous system ([@B120]). Several variants of *NRP1*, *NRP2*, and *SEMA3* are identified in severely obese individuals ([@B120]). These variants disrupt the secretion of melanocortin and/or signaling downstream of melanocortin-4-receptor (MC4R) in human embryonic kidney 293 cells. *In vivo* melanocortin is released by pro-opiomelanocortin (POMC) or Neuropeptide Y (NPY)/Agouti-related protein (AgRP) positive neurons in hypothalamus. Melanocortin/MC4R signaling reduces food intake and increase energy expenditure ([@B30]). Deletion of *Nrp2* in POMC neurons reduces energy expenditure and causes weight gain ([@B120]). Hence, the lymphatic and non-lymphatic contribution of NRPs should also be dissected in the context of obesity.

Apelin {#S7.SS4}
------

Apelin is a peptide and a ligand for the orphan G protein-coupled receptor AJP ([@B113]). Apelin and AJP are widely expressed in the brain, intestine, kidney, adipose tissue and vasculature ([@B77]; [@B27]). Apelin/AJP signaling is involved in many physiological processes, including glucose homeostasis, lipid metabolism ([@B117]), obesity ([@B15]; [@B103]), and diabetes ([@B80]). High fat diet-fed *Apln^--/--^* mice were severely obese and had lymphatic and blood vasculature abnormalities ([@B103]).

*In vitro* studies determined that Apelin could stabilize the expression of adherens junction protein VE-Cadherin and reduce fatty acid-induced vascular hyperpermeability ([@B103]). These results suggest that Apelin maintains lymphatic vessel integrity, and inhibits dietary fat absorption and accumulation.

In summary, these observations suggest a context dependent role of lymphatic vasculature in regulating obesity. Nevertheless, additional non-LEC roles for these molecules in regulating metabolism cannot be excluded.

Mouse Models of Obesity With Defective Lymphatic Function {#S8}
=========================================================

As mentioned previously, lymphatic function is abnormal in obese humans ([@B6]). The following mouse studies support those observations and provide mechanistic explanations for obesity-induced lymphatic dysfunction.

Adipokines {#S8.SS1}
----------

Adipocytes secrete signaling molecules such as leptin, adiponectin, and resistin. These signaling molecules are collectively known as adipokines. One of the primary functions of leptin is to activate nerve centers of the brain and promote satiety. *Ob/Ob* mice, which lack leptin develop severe obesity and type 2 diabetes mellitus. [@B104] demonstrated that the lymphatic vessels of *Ob/Ob* mice are dilated and leaky. They further showed that this lymphatic phenotype is due to low nitric oxide (NO) bioavailability ([@B104]).

Adiponectin also plays a role in maintaining lymphatic function ([@B107]). Using tail-injury model Shimizu et al. demonstrated that mice lacking adiponectin were deficient in their ability to clear tissue fluid and had severe tail edema. In contrast, administration of adiponectin promoted the regrowth of lymphatic vessels and reduced edema. Mechanistically, adiponectin activated the phosphorylation of AKT and eNOS through AMPK and promoted the survival and proliferation of LECs. These data suggest that adipokines such as leptin and adiponectin act as modulators of lymphatic function.

High-Fat Diet-Induced Obesity {#S8.SS2}
-----------------------------

Several studies have investigated the influence of high fat diet induced obesity on lymphatic vascular function ([@B81]; [@B14]; [@B102], [@B101]; [@B10]; [@B44]; [@B58]; [@B87]; [@B116]). They overwhelmingly conclude that obesity affects lymphatic vascular formation and function.

High-fat diet aggravates hypercholesterolemia in *ApoE^--/--^* mice. Lymphatic vessels of these hypercholesterolemic mice were defective in their ability to take up interstitial fluid and were leaky ([@B81]). Moreover, collecting lymphatic vessels of these mice lacked smooth muscle cell coverage and had abnormal LVs ([@B81]). Therefore, hypercholesterolemia could inhibit the maturation of lymphatic vessels.

[@B126] demonstrated that high-fat diet-induced obesity resulted in impaired lymphatic fluid uptake and transport, reduced number of LECs in lymph nodes, dysregulated CCL21 gradient and defective immune cell trafficking. Similarly, Detmar and colleagues showed that high-fat diet impaired the contractility of lymphatic vessels and made them non-responsive to mechanostimulation ([@B14]). Thus, high-fat diet could inhibit LEC survival or proliferation and could compromise lymphatic vascular function.

How could obesity affect lymphatic function? Using tail-injury model Detmar and colleagues quantified lymphatic function in high-fat diet-fed mice before they became obese ([@B49]). They determined that lymph transport is identical between control and high-fat diet-fed mice. This important observation indicated that increased number or size of adipocytes, but not serum lipids, is responsible for lymphatic dysfunction in obese mice. Obesity is associated with chronic, low-grade inflammation ([@B127]). [@B102], [@B101] demonstrated that obesity-induced inflammation could compromise lymphatic function. In contrast, inhibition of inflammation increases lymphatic capillary density and restores lymphatic vascular function in high-fat diet-induced obese mice ([@B116]). Taken together, inflammation could play a key role in obesity-induced lymphatic dysfunction. Furthermore, lymphatic dysfunction could also exacerbate inflammation, thus setting up a vicious feedback loop ([Figure 1](#F1){ref-type="fig"}). Compression or increased lymph load caused by adipocyte hypertrophy/hyperplasia could also affect lymphatic function.

Summary and Future Directions {#S9}
=============================

Obesity is a complex disease that is influenced by many parameters ([Figure 1](#F1){ref-type="fig"}). Evidence is clear that the lymphatic vasculature regulates lipid absorption, adipogenesis, and inflammation ([Figure 1](#F1){ref-type="fig"}). It is also clear that obesity could affect lymphatic function. However, whether lymphatic dysfunction could cause obesity is not fully clear. Mouse studies have revealed that while some mutations that cause lymphatic vascular defects could promote obesity, other mutations protect against it. As proteins generally perform multiple functions it is possible that the genes that regulate lymphatic vascular development or functioning could independently regulate metabolism. Additionally, lymphedema causes severe pain and immobility in patients, which in turn could affect energy expenditure and cause weight gain. Due to these complexities carefully controlled clinical studies and mouse experiments are needed to better understand the relationship between lymphatic function and metabolic diseases. This knowledge could significantly impact the lives of millions of lymphedema, lipedema, and obesity patients worldwide.
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